These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36418428)

  • 21. CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT.
    Xiao M; Duhem C; Chammout A; Berchem G; Janji B
    J Cell Biochem; 2022 Jun; 123(6):1025-1031. PubMed ID: 35575054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of CMTM6 protein in hepatocellular carcinoma involving the regulation of the immune microenvironment.
    Wei Z; Guo X; Li D; Wang J; Lin C; Tan C; Wang Y; Zhu X; Tan S
    Int J Biol Macromol; 2024 Aug; 275(Pt 2):133618. PubMed ID: 38971275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
    Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
    Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
    Qian S; Xu J; Zhao S; Yang P; Yang C
    Clin Exp Immunol; 2022 Jan; 207(1):65-71. PubMed ID: 35020842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
    Tang T; Huang X; Zhang G; Lu M; Hong Z; Wang M; Huang J; Zhi X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
    Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
    Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
    Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
    J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
    Liang HY; Chen SL; Cai SH; Zhang SW; Yang X; Wei LJ; Luo RZ; Liu LL
    J Med Virol; 2023 Mar; 95(3):e28605. PubMed ID: 36815510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
    Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
    Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
    Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
    Front Immunol; 2021; 12():673912. PubMed ID: 34108971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and Clinical Significance of
    Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG
    Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir.
    Yamamoto Y; Kakizaki M; Shimizu T; Carreras J; Chiba T; Chamoto K; Kagawa T; Aoki T; Nakamura N; Ando K; Kotani A
    Int Immunol; 2020 Jul; 32(8):519-531. PubMed ID: 32219331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8
    Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K
    Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728
    [No Abstract]   [Full Text] [Related]  

  • 36. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
    Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
    Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
    Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
    Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemokine-like factor-like MARVEL transmembrane domain containing 6: Bioinformatics and experiments
    Meng H; Li S; Li Q; Wang Y; Wang G; Qu Y
    Front Mol Neurosci; 2022; 15():1026927. PubMed ID: 36698778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
    Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y
    Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.